Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 141, Issue 2, 2008, Pages 158-162

  Brandt, M ^a   Abels, C ^d   May, T ^b   Lohmann, K ^d   Schmidts Winkler, I ^d   Hoyme, U B ^c  

^a Representing the participating gynecologists of the Professional Assoc of Gynecologists Thuringia   (Germany)

^b GBP   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d Dr August Wolff GmbH and Co KG Arzneimittel   (Germany)

Author keywords

Adverse events; Antibiotic; Oral; Therapy; Vaginal

Indexed keywords

ARILIN RAPID; METRONIDAZOLE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BITTER TASTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; METALLIC TASTE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; TREATMENT OUTCOME; VAGINA PESSARY; VAGINITIS; VOMITING;

EID: 56249098996     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.07.022     Document Type: Article

References (26)

1. Hay P.E., and Taylor-Robinson D. Defining bacterial vaginosis: to BV or not to BV, that is the question. Int J STD AIDS 7 (1996) 233-235
2. Eckert L.O. Clinical practice. Acute vulvovaginitis. N Engl J Med 21 355 (2006) 1244-1252
3. Leitich H., Bodner-Adler B., Brunbauer M., Kaider A., Egarter C., and Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 189/1 (2003) 139-147
4. Donders G.G.G., Van Bulck B., Caudron J., Londers L., Vereecken A., and Spitz B. Relationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortion. Am J Obstet Gynecol 183 (2000) 431-437
5. Larsson P.G., and Forsum U. Bacterial vaginosis-a disturbed bacterial flora and treatment enigma. APMIS 113/5 (2005) 305-316
6. Boris J., Pahlson C., and Larsson P.-G. Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 5 (1997) 297-302
7. Beigi R.H., Austin M.N., Meyn L.A., Krohn M., and Hillier S.L. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 191 (2004) 1124-1129
8. Centers for Disease Control and Prevention, Guidelines and treatment of sexually transmitted diseases: MMWR Recommendations and Report 2006, 55(RR11):1-94.
9. AWMF-Reg.-Nr. 015/028, Empfehlungen zur bakteriellen Vaginose in Gynäkologie und Geburtshilfe, www.leitlinien.net; 2006.
10. Matilde Sanchez M., and Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med 25 (2006) 1169-1181
11. Brittain E., and Lin D. A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials. Stat Med 24 (2005) 1-10
12. Larsson P.G., Bergman B., Forsum U., and Pahlson C. Treatment of bacterial vaginosis in women with vaginal bleeding complications or discharge and harbouring Mobiluncus. Gynecol Obstet Invest 29 (1990) 296-300
13. Hillier S.L., Lipinski C., Briselden A.M., and Eschenbach D.A. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Am J Obstet Gynecol 81 (1993) 963-967
14. Livengood III C.H., McGregor J.A., Soper D.E., Newton E., and Thomason J.L. Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment. Am J Obstet Gynecol 170 (1994) 759-764
15. Soper D.E., Livengood C., Sheehan K.L., Fenner D.E., Martens M.G., Nelson A.L., et al. Safety and efficacy of MetroGel-Vaginal(R) in the treatment of bacterial vaginosis: a multicenter, randomized, single-blind, parallel comparison. Prim Care Update Ob Gyns 5 (1998) 150
16. Livengood III C.H., Soper D.E., Sheehan K.L., Fenner D.E., Martens M.G., Nelson A.L., et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 26 (1999) 137-142
17. Hanson J.M., McGregor J.A., Hillier S.L., Eschenbach D.A., Kreutner A.K., Galask R.P., et al. Metronidazole for bacterial vaginosis, a comparison of vaginal gel vs. oral therapy. J Reprod Med 45 (2000) 889-896
18. Voorspoels J., Casteels M., Remon J.P., and Temmerman M. Local treatment of bacterial vaginosis with a bioadhesive metronidazole tablet. Eur J Obstet Gynecol Reprod Biol 105 (2002) 64-66
19. Cunningham F.E., Kraus D.M., Brubaker L., and Fischer J.H. Pharmacokinetics of intravaginal metronidazole gel. J Clin Pharmacol 34 11 (1994) 1060-1065
20. Sobel J.D., Ferris D., Schwebke J., et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 194 5 (2006) 1283-1289
21. Swedberg J., Steiner J.F., Tackwell K.R., and Batts D.H. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 254 (1985) 1046-1049
22. Schmitt C., Sobel J.D., and Merlwether C. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 85 (1992) 1077-1080
23. Paavonen J., Mangioni C., Martin M.A., and Wajszczuk C.P. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 96 (2000) 256-260
24. Alper M.M., Barwin B.N., McLean W.M., McGilveray I.J., and Sved S. Systemic absorption of metronidazole by the vaginal route. Obstet Gynecol 65 (1985) 781-784
25. Edelman D.A., and North B.B. Treatment of bacterial vaginosis with intravaginal sponges containing metronidazole. J Reprod Med 34 (1989) 341-344
26. Ferris D.G., Litaker M.S., Woodward L., Mathis D., and Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 41/5 (1995) 443-449